CorMedix Inc.(CRMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRMD CorMedix Inc.

Pre-Mkt 03-23 06:03:24 EDT

6.25

-0.05

-0.79%

High6.33	Low6.16	Vol2.01M
Open6.21	D1 Closing6.30	Amplitude2.64%
Mkt Cap492.43M	Tradable Cap460.59M	Total Shares78.79M
T/O12.58M	T/O Rate2.73%	Tradable Shares73.69M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CRMD","market":"US","secType":"STK","nameCN":"CorMedix Inc.","latestPrice":6.25,"timestamp":1774036800000,"preClose":6.3,"halted":0,"volume":2013044,"delay":0,"changeRate":-0.007936507936507908,"floatShares":73694900,"shares":78789045,"eps":2.04,"marketStatus":"Pre-Mkt","change":-0.05,"latestTime":"03-23 06:03:24 EDT","open":6.21,"high":6.33,"low":6.1635,"amount":12584937.109579999,"amplitude":0.026429,"askPrice":7.04,"askSize":59,"bidPrice":5.56,"bidSize":161,"shortable":3,"etf":0,"ttmEps":2.04,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1774272600000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1273723200000,"exchange":"NASDAQ","adjPreClose":6.25,"postHourTrading":{"tag":"盘后","latestPrice":6.222,"preClose":6.25,"latestTime":"18:46 EDT","volume":87870,"amount":549134.7477,"timestamp":1774046808255,"change":-0.028,"changeRate":-0.00448,"amplitude":0.00448},"volumeRatio":1.4259635940001754,"impliedVol":0.3151,"impliedVolPercentile":0.012},"requestUrl":"/m/hq/s/CRMD","defaultTab":"news","newsList":[{"id":"2617767653","title":"CorMedix affirms FY26 revenue view of $300M-$320M, consensus $308.7M","url":"https://stock-news.laohu8.com/highlight/detail?id=2617767653","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617767653?lang=en_us&edition=fundamental","pubTime":"2026-03-07 06:20","pubTimestamp":1772835658,"startTime":"0","endTime":"0","summary":"Ahead of the company’s upcoming investor conference presentations next week, CorMedix (CRMD) also maintains its FY27 DefenCath sales outlook of $15...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cormedix-affirms-fy26-revenue-view-of-300m-320m-consensus-308-7m-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cormedix-affirms-fy26-revenue-view-of-300m-320m-consensus-308-7m-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CRMD"],"gpt_icon":0},{"id":"2617634493","title":"CorMedix price target lowered to $13 from $15 at Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2617634493","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617634493?lang=en_us&edition=fundamental","pubTime":"2026-03-07 01:05","pubTimestamp":1772816752,"startTime":"0","endTime":"0","summary":"Leerink lowered the firm’s price target on CorMedix (CRMD) to $13 from $15 and keeps an Outperform rating on the shares. Published first on TheFly ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cormedix-price-target-lowered-to-13-from-15-at-leerink-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cormedix-price-target-lowered-to-13-from-15-at-leerink-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRMD","BK4007"],"gpt_icon":0},{"id":"2617468033","title":"Cormedix (CRMD) Receives a Buy from RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2617468033","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617468033?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:37","pubTimestamp":1772800624,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Leonid Timashev maintained a Buy rating on Cormedix yesterday and set a price target of $13.00. The company’s shares closed yes...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cormedix-crmd-receives-a-buy-from-rbc-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cormedix-crmd-receives-a-buy-from-rbc-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRMD","LU1267930573.SGD","LU0708994859.HKD","LU0310800379.SGD","BK4207","LU0029864427.USD","BK4007","LU0128525929.USD"],"gpt_icon":0},{"id":"2617668458","title":"CorMedix Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2617668458","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617668458?lang=en_us&edition=fundamental","pubTime":"2026-03-06 18:59","pubTimestamp":1772794740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 06, 2026 05:59 ET (10:59 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CRMD"],"gpt_icon":0},{"id":"2617524542","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Altimmune (ALT), Rhythm Pharmaceuticals (RYTM) and Cormedix (CRMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617524542","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617524542?lang=en_us&edition=fundamental","pubTime":"2026-03-06 00:30","pubTimestamp":1772728250,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Altimmune (ALT – Research Report), Rhythm Pharmaceuticals (RYTM –...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-altimmune-alt-rhythm-pharmaceuticals-rytm-and-cormedix-crmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-altimmune-alt-rhythm-pharmaceuticals-rytm-and-cormedix-crmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","BK4599","BK4581","LU1878469433.USD","BK4139","XBI","BK4588","LU0128526141.USD","BK4007","BK4137","BK4585","LU0029874061.USD","HCSG","ALT","CRMD","LABU","RYTM"],"gpt_icon":0},{"id":"2617525663","title":"CorMedix Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2617525663","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617525663?lang=en_us&edition=fundamental","pubTime":"2026-03-05 22:31","pubTimestamp":1772721106,"startTime":"0","endTime":"0","summary":"CorMedix Inc reports results for the quarter ended December 31 - Earnings SummaryCorMedix Inc CRMD.OQ reported quarterly adjusted earnings of 18 cents per share for the quarter ended December 31, lowe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nL8N3ZT1P8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CRMD"],"gpt_icon":0},{"id":"2617554237","title":"CORRECTED-Pharmaceutical firm CorMedix misses Q4 profit expectations, reiterates 2026 revenue forecast","url":"https://stock-news.laohu8.com/highlight/detail?id=2617554237","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617554237?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:39","pubTimestamp":1772714364,"startTime":"0","endTime":"0","summary":"Pharmaceutical firm CorMedix misses Q4 profit expectations, reiterates 2026 revenue forecastOverviewBiopharmaceutical firm's Q4 2025 net revenue was $128.6 mln, driven by DefenCath salesQ4 net income...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nL1N3ZT0LT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4585","LU0203345920.USD","BK4567","CRMD","BK4588","LU0154245756.USD","LU0154245673.USD","LU0203347892.USD","CMI","BK4149","BK4533"],"gpt_icon":0},{"id":"2617544706","title":"Cormedix Q4 EPS $0.18 May Not Compare To $0.82 Estimate, Sales $128.600M Beat $127.022M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2617544706","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617544706?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:32","pubTimestamp":1772713928,"startTime":"0","endTime":"0","summary":"Cormedix Q4 EPS $0.18 May Not Compare To $0.82 Estimate, Sales $128.600M Beat $127.022M Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51062750/cormedix-q4-eps-0-18-may-not-compare-to-0-82-estimate-sales-128-600m-beat-127-022m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRMD","BK4007"],"gpt_icon":0},{"id":"2617220544","title":"CorMedix’s CRMD Q4 net revenue hits USD 128.6 million, up 312%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617220544","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617220544?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:30","pubTimestamp":1772713836,"startTime":"0","endTime":"0","summary":"CorMedix’s CRMD Q4 net revenue hits USD 128.6 million, up 312%               CorMedix (CRMD) reported Q4 2025 net revenue of USD 128.6 million, including USD 91.2 million from DefenCath sales and USD ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL9kH06J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRMD","BK4007","BK4112","BK4585","SG9999014005.SGD","SG9999014013.SGD","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4588","LU0314104364.USD","IE00B64PRP62.GBP","NDAQ","IE00BKPKM429.USD","SG9999014021.USD","IE00BGHQF748.EUR","SG9999014039.USD","LU2210149790.SGD","LU2095319765.USD"],"gpt_icon":0},{"id":"2617544228","title":"CorMedix Q4 Operating Expenses USD -48.182 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2617544228","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617544228?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:30","pubTimestamp":1772713801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nPLXEC75BC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRMD","BK4007"],"gpt_icon":0},{"id":"2617542897","title":"CorMedix Inc: Q4 Net Revenue $128.6 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2617542897","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617542897?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:30","pubTimestamp":1772713801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nPLXEC75BC:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CRMD"],"gpt_icon":0},{"id":"2617442105","title":"CorMedix Q4 Basic EPS USD 0.18","url":"https://stock-news.laohu8.com/highlight/detail?id=2617442105","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617442105?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:30","pubTimestamp":1772713801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nPLXEC75BC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRMD","BK4007"],"gpt_icon":0},{"id":"2617154288","title":"CorMedix Inc - Reiterates 2026 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2617154288","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617154288?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:30","pubTimestamp":1772713801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nPLXEC75BC:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CRMD"],"gpt_icon":0},{"id":"2617139542","title":"CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2617139542","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617139542?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:30","pubTimestamp":1772713800,"startTime":"0","endTime":"0","summary":" Q4 2025 Net Revenue of $128.6 million   Pro Forma Full Year 2025 Net Revenue of $401.3 million   Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million   Conference Call Scheduled for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/05/3250043/0/en/CorMedix-Inc-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRMD","BK4007"],"gpt_icon":0},{"id":"2617545487","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2617545487","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617545487?lang=en_us&edition=fundamental","pubTime":"2026-03-05 19:00","pubTimestamp":1772708400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·CPI Card Grp                                    4Q       .65   7:00 AM","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALT","BNTX","CGEM","AMPX","CLYM","ATHM","CING","ABM","APYX","COST","BODI","AKA","COO","ARQ","ANNX","AMBQ","CTNM","BETA","CHRS","AQN","BTAI","CTOS","OLPX","BRLT","ALGS","ACET","CRVS","COOK","AMTX","ASMB","CNQ","CANG","CCEC","CRMD","BBCP","CIEN","BLND","ADCT","ACCO","BVS","CASY","AEYE","BJ","BURL","FCEL","BCIC","ALNT","CLAR"],"gpt_icon":1},{"id":"2616330677","title":"CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2616330677","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616330677?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:30","pubTimestamp":1772458200,"startTime":"0","endTime":"0","summary":"BERKELEY HEIGHTS, N.J., March  02, 2026  (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/02/3247400/0/en/CorMedix-Inc-to-Report-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provide-a-Corporate-Update-on-March-5-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CRMD"],"gpt_icon":0},{"id":"2610495065","title":"CorMedix's Growth Outlook Hinges on Trial Data, Prophylaxis Opportunity, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2610495065","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610495065?lang=en_us&edition=fundamental","pubTime":"2026-02-12 01:57","pubTimestamp":1770832635,"startTime":"0","endTime":"0","summary":"CorMedix's  near-term growth prospects will be shaped by upcoming clinical data, particularly around the potential use of Rezzayo to prevent invasive fungal infections in high-risk transplant and cancer patients, RBC Capital Markets said Tuesday in a report.At the company's research and development event, clinicians said Rezzayo's clean safety profile, few interactions with other medications, high initial drug levels, and once-weekly IV dosing could make it well-suited for prophylaxis in immunocompromised patients, the report said. Management estimates the prophylaxis market at $2 billion, while RBC models about $150 million in potential revenue based on a 10% share.Physicians also highlighted the drug's advantages in treating invasive fungal infections, noting that Rezzayo is currently used mostly in later-line settings, the report said. Broader adoption in treatment will likely require additional data and insurer coverage decisions, RBC said.For DefenCath, management and panelists po","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRMD","BK4007"],"gpt_icon":0},{"id":"2610693267","title":"CorMedix Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2610693267","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610693267?lang=en_us&edition=fundamental","pubTime":"2026-02-11 20:19","pubTimestamp":1770812340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 11, 2026 07:19 ET (12:19 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRMD","BK4007"],"gpt_icon":0},{"id":"2608898579","title":"CorMedix Authorizes Up to $75 Million Stock Buyback; Shares Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2608898579","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608898579?lang=en_us&edition=fundamental","pubTime":"2026-02-02 23:10","pubTimestamp":1770045022,"startTime":"0","endTime":"0","summary":"CorMedix  said its board approved a stock repurchase program of up to $75 million.The buyback, which may begin as early as Q1, is authorized through Dec. 31, 2027, the company said Monday in a statement.CorMedix shares rose 6.6% in Monday trading.Price: 8.28, Change: +0.52, Percent Change: +6.64","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRMD","BK4007"],"gpt_icon":0},{"id":"2608864789","title":"CorMedix board authorizes share repurchase program of up to $75M","url":"https://stock-news.laohu8.com/highlight/detail?id=2608864789","media":"TIPRANKS","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608864789?lang=en_us&edition=fundamental","pubTime":"2026-02-02 21:35","pubTimestamp":1770039315,"startTime":"0","endTime":"0","summary":"CorMedix (CRMD) Therapeutics announced its Board of Directors has approved a share repurchase program, which authorizes the Company to repurchase u...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cormedix-board-authorizes-share-repurchase-program-of-up-to-75m-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cormedix-board-authorizes-share-repurchase-program-of-up-to-75m-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRMD","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cormedix.com","stockEarnings":[{"period":"1week","weight":-0.031},{"period":"1month","weight":-0.1283},{"period":"3month","weight":-0.48},{"period":"6month","weight":-0.442},{"period":"1year","weight":-0.4245},{"period":"ytd","weight":-0.4626}],"compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":-0.055},{"period":"3month","weight":-0.047},{"period":"6month","weight":-0.0228},{"period":"1year","weight":0.1469},{"period":"ytd","weight":-0.0489}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.133293},{"month":2,"riseRate":0.5,"avgChangeRate":0.066552},{"month":3,"riseRate":0.5,"avgChangeRate":0.036608},{"month":4,"riseRate":0.466667,"avgChangeRate":-0.013888},{"month":5,"riseRate":0.2,"avgChangeRate":-0.123071},{"month":6,"riseRate":0.5625,"avgChangeRate":0.053114},{"month":7,"riseRate":0.4375,"avgChangeRate":0.055385},{"month":8,"riseRate":0.5625,"avgChangeRate":0.025363},{"month":9,"riseRate":0.375,"avgChangeRate":0.027376},{"month":10,"riseRate":0.4375,"avgChangeRate":0.043001},{"month":11,"riseRate":0.4375,"avgChangeRate":0.046811},{"month":12,"riseRate":0.4375,"avgChangeRate":0.057824}],"exchange":"NASDAQ","name":"CorMedix Inc.","nameEN":"CorMedix Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CorMedix Inc.(CRMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CorMedix Inc.(CRMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CorMedix Inc.,CRMD,CorMedix Inc.股票,CorMedix Inc.股票老虎,CorMedix Inc.股票老虎国际,CorMedix Inc.行情,CorMedix Inc.股票行情,CorMedix Inc.股价,CorMedix Inc.股市,CorMedix Inc.股票价格,CorMedix Inc.股票交易,CorMedix Inc.股票购买,CorMedix Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CorMedix Inc.(CRMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CorMedix Inc.(CRMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}